skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The role of glatiramer acetate in the early treatment of multiple sclerosis

Review

(2312) Views  (502) Full article downloads

Authors: David W Brandes

Published Date June 2010 Volume 2010:6(1) Pages 329 - 336
DOI: http://dx.doi.org/10.2147/NDT.S5898

David W Brandes

Hope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USA

Abstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process.

Keywords: glatiramer acetate, early treatment, multiple sclerosis








Readers of this article also read:

Potential renovascular hypertension, space missions, and the role of magnesium
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Current and emerging treatment options in the management of Friedreich ataxia
Current and emerging therapies for the treatment of myasthenia gravis
Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine
Everolimus-eluting stents: update on current clinical studies
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice